MedTrace Logo

Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04731935 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-08-19

No results posted yet for this study

Summary

The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.

Conditions

  • Opioid-use Disorder
  • Opioid Withdrawal

Interventions

DEVICE

Sparrow Therapy System

Transcutaneous auricular neurostimulation

Sponsors & Collaborators

  • Spark Biomedical, Inc.

    lead INDUSTRY

Principal Investigators

  • Navid Khodaparast, PhD · Spark Biomedical, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2021-05-26
Completion
2021-05-26
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731935 on ClinicalTrials.gov